Jazz Pharmaceuticals

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Onera Health, Inc. specializes in providing innovative sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, Onera Health has developed advanced sleep diagnostic patch systems that collect and analyze sleep data. These systems not only enhance the diagnosis of sleep-related ailments but also have potential applications in monitoring various chronic health conditions. By delivering comprehensive sleep test data to healthcare providers, Onera Health aims to improve patient care and reduce healthcare costs, ultimately enhancing the health and quality of life for individuals globally.

GW Pharmaceuticals is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of innovative therapeutics derived from its proprietary cannabinoid platform. Its primary product, Epidiolex, is an oral solution used to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients aged one year and older, and it is also under review for the treatment of tuberous sclerosis complex. In Europe, the product is marketed as Epidyolex. The company also offers Sativex, which is used for managing spasticity due to multiple sclerosis, and is advancing various cannabinoid product candidates aimed at treating conditions such as schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. GW Pharmaceuticals operates primarily in Europe, the United Kingdom, and the United States, and has been established since 1998.

Cavion LLC is a clinical-stage pharmaceutical company focused on developing therapies for neurological and rare genetic diseases by modulating T-type calcium channels (Cav3). The company’s lead product, CX-8998, targets these channels in the nervous system, and Cavion aims to deliver innovative non-opioid treatments for conditions such as neuropathic pain, essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Founded in 2003 and based in Charlottesville, Virginia, with an additional office in Cambridge, Massachusetts, Cavion was previously known as Tau Therapeutics LLC until its name change in 2014. The company is notable for being the first to target Cav3 ion channels in the treatment of solid tumors, with ongoing Phase 1 clinical trials investigating its potential in brain cancer. Cavion's approach leverages advanced chemistry and clinical expertise to enhance the efficacy of existing therapies, such as chemotherapy and radiation, against solid tumor cancers. As of August 2019, Cavion operates as a subsidiary of Jazz Pharmaceuticals plc.

Onera Health, Inc. specializes in providing innovative sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, Onera Health has developed advanced sleep diagnostic patch systems that collect and analyze sleep data. These systems not only enhance the diagnosis of sleep-related ailments but also have potential applications in monitoring various chronic health conditions. By delivering comprehensive sleep test data to healthcare providers, Onera Health aims to improve patient care and reduce healthcare costs, ultimately enhancing the health and quality of life for individuals globally.

Celator Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company specializes in creating optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Celator's product pipeline includes VYXEOS, a liposomal formulation of irinotecan and floxuridine, currently undergoing Phase III clinical trials for acute myeloid leukemia (AML). Additionally, CPX-351, another liposomal formulation of cytarabine and daunorubicin, is also in Phase III studies for AML. CPX-1, a combination of irinotecan and floxuridine, has completed Phase II trials targeting colorectal cancer. The company also has a preclinical candidate, CPX-8, which is a nanoparticle formulation of docetaxel. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in the development of biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on reformulating existing drugs and creating new chemical entities, employing its expertise to navigate regulatory strategies that streamline the approval process. By collaborating closely with regulatory bodies such as the FDA, the company aims to minimize unexpected challenges and accelerate the implementation of its clinical programs. Through its innovative approach, Arrivo BioVentures seeks to meet the demands of the biotechnology sector while prioritizing the improvement of patient outcomes.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Gentium S.p.A. is biopharmaceutical company specializing in the discovery, research, development and manufacture of active ingredients derived from natural sources as potential therapeutic agents. Gentium operates independently as a research facility and production plant for drug substance pharmaceuticals in Villa Guardia, near Como, Italy.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Azur Pharma is a privately held pharmaceutical company focused on improving patients' lives through the development and marketing of specialized therapeutic products. The company aims to address unmet medical needs by identifying, developing, and commercializing meaningful biopharmaceuticals. Its portfolio includes treatments for conditions such as cataplexy, excessive daytime sleepiness, acute lymphoblastic leukemia, and severe hepatic veno-occlusive disease. Azur Pharma's strategy involves evaluating and selectively acquiring late-stage development and approved pharmaceutical products, enhancing their value to better serve patients.

Orphan Medical is a healthcare company focused on developing specialty pharmaceuticals aimed at treating sleep disorders, pain, and other central nervous system conditions. By concentrating on these specific areas, the company seeks to address unmet medical needs and improve patient outcomes through innovative drug therapies.